Evidence map›Paper›PMID 28721392›Full record

ArticleHeliyon2017

The response to Typhi Vi vaccination is compromised in individuals with primary immunodeficiency.

Jeevani Kumarage, Suranjith L Seneviratne, Vijitha Senaratne, Amitha Fernando, Kirthi Gunasekera, Bandu Gunasena, Padmalal Gurugama, Sudath Peiris, Antony R Parker, Stephen Harding and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Jeevani KumarageDepartment of Immunology, Medical Research Institute, Colombo 8, Sri Lanka.
Suranjith L SeneviratneInstitute of Immunity and Transplantation, Royal Free Hospital, London, UK.
Vijitha SenaratneNational Hospital for Respiratory Diseases, Walisara, Sri Lanka.
Amitha FernandoNational Hospital of Sri Lanka/Central Chest Clinic, Colombo, Sri Lanka.
Kirthi GunasekeraNational Hospital of Sri Lanka/Central Chest Clinic, Colombo, Sri Lanka.
Bandu GunasenaNational Hospital for Respiratory Diseases, Walisara, Sri Lanka.
Padmalal GurugamaDepartment of Clinical Biochemistry and Immunology, Cambridge University Hospitals NHS Foundation Trust, Hills road, Cambridge, UK.
Sudath PeirisEpidemiology Unit, Ministry of Health, Sri Lanka.
Antony R ParkerThe Binding Site Group Limited, 8 Calthorpe Road, Edgbaston, Birmingham, B15 1QT, UK.
Stephen HardingThe Binding Site Group Limited, 8 Calthorpe Road, Edgbaston, Birmingham, B15 1QT, UK.
Nilhan Rajiva de SilvaDepartment of Immunology, Medical Research Institute, Colombo 8, Sri Lanka.
National Hospital of Sri Lanka · LKMedical Research Institute · LKCambridge University Hospitals NHS Foundation Trust · GBUniversity of Colombo · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurement of an individuals ability to respond to polysaccharide antigens is a crucial test to determine adaptive immunity. Currently the response to Pneumovax

Indexed as

Biological sciencesHealth sciencesImmunologyInfectious diseaseMedicinePediatricsVaccines

Identifiers

PMID28721392
PMCPMC5486435
OpenAlexW2647159074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.